• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

作者信息

Powles T

机构信息

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

出版信息

Ann Oncol. 2021 Mar;32(3):422-423. doi: 10.1016/j.annonc.2020.11.016. Epub 2020 Nov 30.

DOI:10.1016/j.annonc.2020.11.016
PMID:33271289
Abstract
摘要

相似文献

1
Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.欧洲肿瘤内科学会（ESMO）肾细胞癌临床实践指南关于卡博替尼和纳武单抗用于一线透明细胞肾细胞癌的最新电子更新：肾细胞癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Mar;32(3):422-423. doi: 10.1016/j.annonc.2020.11.016. Epub 2020 Nov 30.
2
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.纳武利尤单抗联合卡博替尼与舒尼替尼用于晚期肾细胞癌一线治疗（CheckMate 9ER）：一项开放标签、随机、III 期临床试验的长期随访结果。
Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7.
3
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.纳武利尤单抗和卡博替尼治疗转移性肾细胞癌的真实世界结局：来自国际转移性肾细胞癌数据库联盟的结果。
Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595. Epub 2019 Apr 1.
4
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma.纳武利尤单抗对比卡博替尼：转移性肾细胞癌总生存期的比较
PLoS One. 2016 Jun 6;11(6):e0155389. doi: 10.1371/journal.pone.0155389. eCollection 2016.
5
Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma.更新的欧洲泌尿外科学会肾癌指南：纳武利尤单抗联合卡博替尼加入免疫检查点抑制联合治疗用于治疗初治转移性透明细胞肾细胞癌。
Eur Urol. 2021 Mar;79(3):339-342. doi: 10.1016/j.eururo.2020.12.005. Epub 2020 Dec 24.
6
The nivolumab/cabozantinib combination and the future of doublets in advanced renal cell cancer treatment.纳武利尤单抗/卡博替尼联合疗法与晚期肾细胞癌治疗中双药联合方案的未来
J Oncol Pharm Pract. 2021 Sep;27(6):1553-1554. doi: 10.1177/10781552211027942. Epub 2021 Jun 24.
7
Efficacy of Cabozantinib in Metastatic Papillary Renal Cell Carcinoma Following Ineffective Treatment With Initial Therapy of Nivolumab and Ipilimumab.卡博替尼治疗纳武利尤单抗和伊匹单抗初始治疗失败的转移性乳头状肾细胞癌的疗效。
In Vivo. 2021 May-Jun;35(3):1743-1747. doi: 10.21873/invivo.12433.
8
[New EMA approval: Nivolumab plus Cabozantinib for advanced renal clear cell carcinoma].[欧洲药品管理局新批准：纳武单抗联合卡博替尼用于晚期肾透明细胞癌]
Bull Cancer. 2021 Nov;108(11):991-993. doi: 10.1016/j.bulcan.2021.05.005. Epub 2021 Sep 17.
9
CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma.卡博替尼联合纳武利尤单抗一线治疗晚期肾细胞癌的前瞻性、IV 期研究（CaboCombo：一项评估卡博替尼联合纳武利尤单抗一线治疗晚期肾细胞癌的前瞻性、IV 期研究）
Future Oncol. 2024 Apr;20(13):811-819. doi: 10.2217/fon-2023-0353. Epub 2023 Jul 5.
10
Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States.美国一线纳武利尤单抗联合卡博替尼治疗晚期肾细胞癌的成本效果分析。
Adv Ther. 2021 Dec;38(12):5662-5670. doi: 10.1007/s12325-021-01926-0. Epub 2021 Oct 18.

引用本文的文献

1
Renal cell carcinoma accompanied by aldosterone-secreting contralateral adrenal metastasis: a case report.肾细胞癌伴分泌醛固酮的对侧肾上腺转移：一例报告
J Med Case Rep. 2025 Jul 9;19(1):331. doi: 10.1186/s13256-025-05396-8.
2
The role of programmed cell death in renal cancer: a bibliometric perspective (1998-2024).程序性细胞死亡在肾癌中的作用：文献计量学视角（1998 - 2024年）
Discov Oncol. 2025 May 23;16(1):889. doi: 10.1007/s12672-025-02610-3.
3
Up-regulation of Cuproptosis-related lncRNAS in Patients Receiving Immunotherapy for Metastatic Clear Cell Renal Cell Carcinoma Indicates Progressive Disease.
转移性透明细胞肾细胞癌接受免疫治疗患者中铜死亡相关长链非编码RNA的上调表明疾病进展。
In Vivo. 2025 Jan-Feb;39(1):146-151. doi: 10.21873/invivo.13812.
4
Metastatic sites and clinical outcomes in renal cell carcinoma patients receiving immune-based combinations: the MOUSEION-08 study.接受免疫联合治疗的肾细胞癌患者的转移部位和临床结局：MOUSEION-08研究
Clin Exp Metastasis. 2024 Dec 30;42(1):9. doi: 10.1007/s10585-024-10327-w.
5
The efficacy and safety of belzutifan inhibitor in patients with advanced or metastatic clear cell renal cell carcinoma: a meta-analysis.贝利尤单抗抑制剂治疗晚期或转移性透明细胞肾细胞癌患者的疗效和安全性：一项荟萃分析。
BMC Pharmacol Toxicol. 2024 Dec 20;25(1):100. doi: 10.1186/s40360-024-00828-5.
6
Impact of time-of-day administration of immunotherapy on survival in metastatic renal cell carcinoma: the MOUSEION-09 meta-analysis.免疫疗法给药时间对转移性肾细胞癌生存的影响：MOUSEION - 09荟萃分析
Clin Exp Metastasis. 2024 Dec 16;42(1):3. doi: 10.1007/s10585-024-10322-1.
7
Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective.非透明细胞肾细胞癌的基因组分析与分子特征：临床视角的叙述性综述
Ther Adv Med Oncol. 2024 Nov 19;16:17588359241298500. doi: 10.1177/17588359241298500. eCollection 2024.
8
Osteonecrosis of the jaw in patients with clear cell renal cell carcinoma treated with targeted agents: a case series and large-scale pharmacovigilance analysis.接受靶向药物治疗的透明细胞肾细胞癌患者颌骨骨坏死：病例系列及大规模药物警戒分析
Front Pharmacol. 2024 Oct 29;15:1309148. doi: 10.3389/fphar.2024.1309148. eCollection 2024.
9
International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).转移性肾细胞癌患者的国际多中心真实世界 REGistry - Meet-URO 33 研究（REGAL 研究）。
BMC Cancer. 2024 Jun 24;24(1):757. doi: 10.1186/s12885-024-12319-1.
10
Deep learning-based pathological prediction of lymph node metastasis for patient with renal cell carcinoma from primary whole slide images.基于深度学习的原发性全切片图像肾细胞癌患者淋巴结转移的病理预测。
J Transl Med. 2024 Jun 14;22(1):568. doi: 10.1186/s12967-024-05382-6.